Lack of association between Glu298Asp polymorphism and coronary artery disease in North Indians.
Nitric Oxide (NO) is an important molecule carrying number of different functions in humans. Published studies suggest that it may inhibit several key steps involved in the pathogenesis of atherosclerosis. Inhibition or reduction of NO due to Glu298Asp polymorphism may accelerate atherosclerosis. The aim of this study was to determine whether Glu298Asp polymorphism is implicated in the pathogenesis of coronary artery disease (CAD) among North Indian population from the state of Uttar Pradesh, India. We selected 253 CAD patients and 174 healthy, normotensive, non-diabetic controls, which were matched for gender and ethnicity. The Glu298Asp (rs1799983) variant was detected by genotyping subjects, using a polymerase chain reaction followed by restriction fragment length polymorphism. There was no significant difference found in the genotypic and allelic frequencies between patients and controls. Our study indicated that Glu298Asp polymorphism does not play any critical role in the pathogenesis of CAD, at least in North Indian population.
Department of Cardiology, Sanjay Gandhi PGIMS, Lucknow, Uttar Pradesh, India.
Himanshu
H
Rai
Jacqui
J
Fitt
A K
AK
Sharma
Nakul
N
Sinha
Sudeep
S
Kumar
C M
CM
Pandey
Suraksha
S
Agrawal
Sarabjit
S
Mastana
D000328:Adult; D019943:Amino Acid Substitution / Q000235:genetics*; D016022:Case-Control Studies; D003324:Coronary Artery Disease / Q000201:enzymology / Q000235:genetics*; D003710:Demography; D004587:Electrophoresis, Agar Gel; D005260:Female; D005787:Gene Frequency / Q000235:genetics; D056726:Genetic Association Studies; D020022:Genetic Predisposition to Disease; D006801:Humans; D007194:India; D008297:Male; D008875:Middle Aged; D052250:Nitric Oxide Synthase Type III / Q000235:genetics; D016017:Odds Ratio; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D012907:Smoking / Q000009:adverse effects / Q000235:genetics
C496314:NOS3 protein, human; D052250:Nitric Oxide Synthase Type III